EGFR and non-small cell lung carcinoma: Considering the oncogene mutations and other factors in NSCLC patients, various targeted therapies have been developed such as EGFR specific TKIs targeting EGFR specific mutations, anaplastic lymphoma kinase (ALK) inhibitor targeting ALK-positive patients, and immune checkpoint blockers which substantially improved the quality of life in NSCLC patients over the past 20 years 31-33.